2obq: Difference between revisions

New page: left|200px<br /><applet load="2obq" size="350" color="white" frame="true" align="right" spinBox="true" caption="2obq, resolution 2.5Å" /> '''Discovery of the HCV ...
 
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
The structures of both the native holo-HCV NS3/4A protease domain and the, protease domain with a serine 139 to alanine (S139A) mutation were solved, to high resolution. Subsequently, structures were determined for a series, of ketoamide inhibitors in complex with the protease. The changes in the, inhibitor potency were correlated with changes in the buried surface area, upon binding the inhibitor to the active site. The largest contribution to, the binding energy arises from the hydrophobic interactions of the P1 and, P2 groups as they bind to the S1 and S2 pockets [the numbering of the, subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc., London, Ser. B 1970, 257, 249-264]. This correlation of the changes in, potency with increased buried surface area contributed directly to the, design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is, currently in clinical trials.
The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249-264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials.


==About this Structure==
==About this Structure==
Line 15: Line 15:
[[Category: Arasappan, A.]]
[[Category: Arasappan, A.]]
[[Category: Bennett, F.]]
[[Category: Bennett, F.]]
[[Category: Beyer, B.M.]]
[[Category: Beyer, B M.]]
[[Category: Bogen, S.F.]]
[[Category: Bogen, S F.]]
[[Category: Chen, K.]]
[[Category: Chen, K.]]
[[Category: Fischmann, T.]]
[[Category: Fischmann, T.]]
Line 25: Line 25:
[[Category: Jao, E.]]
[[Category: Jao, E.]]
[[Category: Liu, Y.]]
[[Category: Liu, Y.]]
[[Category: Love, R.G.]]
[[Category: Love, R G.]]
[[Category: Madison, V.]]
[[Category: Madison, V.]]
[[Category: Malcolm, B.]]
[[Category: Malcolm, B.]]
[[Category: Myers, Jr., J.]]
[[Category: Myers, Jr., J.]]
[[Category: Njoroge, F.G.]]
[[Category: Njoroge, F G.]]
[[Category: Pichardo, J.]]
[[Category: Pichardo, J.]]
[[Category: Prongay, A.J.]]
[[Category: Prongay, A J.]]
[[Category: Prosise, W.W.]]
[[Category: Prosise, W W.]]
[[Category: Ramanathan, L.]]
[[Category: Ramanathan, L.]]
[[Category: Saksena, A.K.]]
[[Category: Saksena, A K.]]
[[Category: Senior, M.]]
[[Category: Senior, M.]]
[[Category: Strickland, C.]]
[[Category: Strickland, C.]]
[[Category: Taremi, S.S.]]
[[Category: Taremi, S S.]]
[[Category: Venkatraman, S.]]
[[Category: Venkatraman, S.]]
[[Category: Weber, P.C.]]
[[Category: Weber, P C.]]
[[Category: Yang, R.]]
[[Category: Yang, R.]]
[[Category: Yao, N.]]
[[Category: Yao, N.]]
Line 50: Line 50:
[[Category: viral protein]]
[[Category: viral protein]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 14:21:16 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:16:40 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA